In Wednesday’s Wall Street session, Unicycive Therapeutics Inc (NASDAQ:UNCY) shares traded at $0.67, down -2.80% from the previous session.
UNCY stock price is now 6.76% away from the 50-day moving average and 16.97% away from the 200-day moving average. The market capitalization of the company currently stands at $84.38M.
With the price target of $6, Guggenheim recently initiated with Buy rating for Unicycive Therapeutics Inc (NASDAQ: UNCY). On April 04, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $9
A total of 17.08% of the company’s stock is owned by insiders.
During the past 12 months, Unicycive Therapeutics Inc has had a low of $0.20 and a high of $1.10. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 1.64, and a quick ratio of 1.64. The fifty day moving average price for UNCY is $0.62524 and a two-hundred day moving average price translates $0.57067 for the stock.
The latest earnings results from Unicycive Therapeutics Inc (NASDAQ: UNCY) was released for 2025-03-31. The company reported revenue of $7.99 million for the quarter, compared to $9.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.2 percent.
